What Wall Street is saying about AVEO Pharmaceuticals, Inc. (AVEO)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock is presently standing at about $2.22 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 2 analysts covering the company is $2.50, which suggests the stock could still rise over 11 percent. The highest analyst price target is $3.00, which implies a rally of 65 percent. And a quick view of analyst notes show that 1 are rating the stock a buy while 1 rate AVEO a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.

Piper Jaffray analysts provided their view on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm issued a Overweight rating to this company in a research note released on May 19, 2016. FBR Capital analysts disclosed their opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) recently. The rating firm gave a Outperform rating to this stock in a research note published on Mar 30, 2016. According to a research note disclosed on Mar 09, 2015, analysts at RBC Capital Mkts have upped their rating on these shares from Underperform to Sector Perform.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its 10% Owner Sonsini Peter W. Purchased 16,362,694 company shares for 3,000,000, in a transaction on Mar 28. Following the transaction, the 10% Owner is left with a stake of 6,000,000 shares, currently valued at $13,320,000. Meanwhile, 10% Owner Viswanathan Ravi purchased 16,362,694 shares worth $3,000,000, through a transaction dated Mar 28. Following the completion of the transaction, the insider is left with a stake of 6,000,000 shares, amounting $13,320,000. AVEO 10% Owner Sakoda Jon also purchased 16,362,694 shares, at a stock price of $0.50. This transaction occurred on Mar 28 totals $3,000,000. After this transaction, the insider’s stake stands at 6,000,000 shares, with a market value of $13,320,000.

Executives hold 2.15 percent of the stock. NEA MANAGEMENT COMPANY, LLC is one of the biggest insider owners in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 16,362,694 shares which have current market value of around $36,325,181.PERCEPTIVE ADVISORS LLC is another major inside shareholder in the company. The insider owns 5,108,808 shares as of 03/31/2017, currently worth $11,341,554. ARMISTICE CAPITAL, LLC is ranked as third insider holder of the stock. This insider holds 4,800,000 shares with a market value around $10,656,000 as of recent close.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Earnings Outlook

In AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s latest quarter, EPS moved to $-0.12 from $-0.07 in preceding quarter and revenues reached at $2.53M compared to $0.13M. Analysts had expected AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post net income of about $-0.12 per share on $0.12M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.17 to $-0.09. That is compared with the $-0.13 in EPS it reported during the same period a year ago.